Hyperthermic intraperitoneal chemotherapy in locally advanced and recurrent ovarian carcinoma: surgical and oncological outcomes in the Indian public healthcare system.
Jyoutishman SaikiaBabul BansalSuryanarayana S V DeoNavin KumarRaghuram KuppusamyAreendam BaruaMukur Dipi RayPublished in: Future oncology (London, England) (2021)
This study analyzed the surgical outcomes after initial implementation of a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) program in government settings in India. Methods: Ovarian cancer patients undergoing cytoreductive surgery and HIPEC from May 2015 to April 2019 were identified from a prospectively maintained database. Treatment characteristics and surgical outcomes were analyzed. Results: The study identified 101 patients. The mean peritoneal cancer index (PCI) was 7 ± 6, with higher PCI scores in primary and recurrent cases. Major morbidities were recorded in 24.7% of patients. High PCI score, completeness of cytoreduction and major morbidities were independent predictors of overall survival in multivariate analysis. Conclusion: The application of HIPEC in limited-resource settings is feasible with acceptable major morbidities. This program should receive similar priority in government systems.
Keyphrases
- locally advanced
- end stage renal disease
- ejection fraction
- newly diagnosed
- coronary artery disease
- acute myocardial infarction
- chronic kidney disease
- patients undergoing
- acute coronary syndrome
- healthcare
- rectal cancer
- emergency department
- percutaneous coronary intervention
- squamous cell carcinoma
- prognostic factors
- radiation therapy
- primary care
- clinical trial
- adipose tissue
- heart failure
- neoadjuvant chemotherapy
- atrial fibrillation
- st segment elevation myocardial infarction
- patient reported outcomes
- lymph node
- st elevation myocardial infarction
- left ventricular
- weight loss
- phase ii study
- electronic health record
- metastatic renal cell carcinoma